Analysts’ average price target for ResMed (RMD) implies 28.2% upside versus the current stock level. The article also notes strong analyst alignment in lifting earnings estimates, supporting a positive bias for the shares even though the price-target metric itself is not always reliable.
Analysts’ average price target for ResMed (RMD) implies 28.2% upside versus the current stock level. The article also notes strong analyst alignment in lifting earnings estimates, supporting a positive bias for the shares even though the price-target metric itself is not always reliable.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
